News


Minoryx Therapeutics receives FDA Orphan Drug Designation for leriglitazone in Friedreich’s Ataxia

Thursday , 17 October 2019

Leriglitazone (MIN-102) is a novel, brain penetrant, orally bioavailable and selective PPAR gamma agonist Second Orphan Drug Designation granted by the FDA for leriglitazone in addition to X-linked adrenoleukodystrophy (X-ALD) Potential for seven years of marketing exclusivity in the USA upon approval in the orphan designation indication Mataró, Barcelona, Spain and Charleroi, Belgium, October 17, 2019 – Minoryx Therapeutics, a company that specializes in the...

READ MORE...


Medicen Paris Region reorganizes its Strategic Areas of Activities (DAS) to bring engineers and doct

Thursday , 10 October 2019

Medicen Paris Region reorganizes its Strategic Areas of Activities (DAS) to bring engineers and doctors closer together New DAS organization within cluster reflects changes in health ecosystem and integrates techno-therapies Paris, France, October 10, 2019 – Medicen Paris Region, Europe’s leading health competitiveness cluster, today announces a reorganization of its Strategic Activities Areas (Domaines d’Activité Stratégiques - DAS), and its governanc...

READ MORE...


Innovative Solution Providers’ symposium focused on immunotherapies

Wednesday , 09 October 2019

News report – Innovative Solution Providers’ symposium focused on immunotherapies   On September 30, 2019, 100 scientific professionals gathered in Paris for the 1st edition of a unique symposium to discuss ‘Innovative & Integrated Solution Providers in Translational Research to Develop Immunotherapies – Toward Next Generation of Solution Providers’.   Exploring the current trends in immunotherapies discovery &a...

READ MORE...


Minoryx Therapeutics completes enrollment in FRAMES phase 2 trial with leriglitazone in Friedreich

Tuesday , 08 October 2019

Recruitment of 39 patients in multicenter European phase 2 trial completed ahead of schedule  Mataró, Barcelona, Spain and Charleroi, Belgium, October 8, 2019 – Minoryx Therapeutics, a company specializing in the development of innovative treatments for orphan central nervous system (CNS) diseases, today announces that it has completed recruitment in the FRAMES phase 2 clinical trial of its novel PPARγ agonist, leriglitazone (MIN-102), in patients with Friedreich&...

READ MORE...


Domain Therapeutics reaches two milestones in multi-target research collaboration with Boehringer In

Monday , 30 September 2019

Less than one year after signing agreement, the GPCR expert has reached key discovery milestones in two independent projects   Strasbourg, France, September 30, 2019 – Domain Therapeutics, a biopharmaceutical company specialized in the discovery and development of new drug candidates targeting transmembrane receptors in neurology, oncology and rare diseases, today announces the achievement of two discovery milestones in its multi-target collaborati...

READ MORE...


Domain Therapeutics invests in Ermium Therapeutics to develop first-in-class CXCR4 candidate for a

Wednesday , 11 September 2019

G Protein Coupled Receptor (GPCR) expert will invest up to €3M ($3.3M) to unlock the therapeutic potential of breakthrough asset   Strasbourg, France, September 11, 2019 – Domain Therapeutics, a biopharmaceutical company specialized in the discovery and development of new drug candidates targeting transmembrane receptors in neurology, oncology and rare diseases, today announces its investment of up to €3M ($3.3M) in Ermium Therapeutics.   Founded in June 2...

READ MORE...


Keranova raises €24M in second round of financing

Tuesday , 10 September 2019

Funds will enable company to finalize regulatory process with view to obtaining CE mark for ultra-fast robotized ophthalmology laser   Saint-Etienne and Lyon, France, September 10, 2019 – Keranova, a company specializing in the development of surgical ophthalmology equipment, today announces that it has raised €24M ($26.5M) in a second round of financing, prompted by its long-standing shareholders Mérieux Equity Partners and Supernova Invest. Financière Arbev...

READ MORE...


Yposkesi’s viral vectors used in gene therapy-based clinical trial 

Monday , 09 September 2019

EuroFanColen researchers published in Nature Medicine first clinical results for Fanconi anemia patients   Corbeil-Essonnes, France, September 9, 2019 – Yposkesi, a leading Contract Development and Manufacturing Organization (CDMO) for preferred access and reserved capacity for cGMP grade viral vector production, today announces it produced the viral vectors used in the gene therapy-based clinical trial in patients with Fanconi anemia. In this study, the authors demonstrat...

READ MORE...


Imcyse reports successful first-in-human Phase 1b study in type 1 diabetes with IMCY-0098

Tuesday , 27 August 2019

Company’s insulin-based Imotope™ IMCY-0098 shows excellent safety profile and promising clinical trends while eliciting immune responses supporting the proposed mode of action   Liège, Belgium, August 27, 2019 – Imcyse, a clinical-stage company developing active and specific immunotherapeutics for the treatment and prevention of severe chronic diseases, today announces the successful completion of its first-in-human Phase 1b study in patients with recent-onse...

READ MORE...


Alizé Pharma 3 raises €67 million ($75 million) in Series A from a strong international syndicat

Wednesday , 31 July 2019

Proceeds will be used to grow company’s team in Lyon and Boston, to advance its current programs in hypoparathyroidism and severe insulin resistance into clinical development, and to further strengthen its product portfolio in rare endocrine and metabolic diseases   Lyon, France, July 31, 2019 - Alizé Pharma 3, a company specialized in developing therapeutic peptides for rare endocrine and metabolic diseases, today announces that it has completed a €67 million ...

READ MORE...


Featured Employers

© 2019 Jobsinpharma - 4ward Technologies Ltd All rights reserved.